Matthew Weston Analyst Performance

Matthew Weston is a stock analyst at UBS Group in the medical sector, covering 2 publicly traded companies. Over the past year, Matthew Weston has issued 2 stock ratings, including and hold recommendations. While full access to Matthew Weston's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matthew Weston's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

3 Last 6 Years

Buy Recommendations

0.00% 0 Buy Ratings

Companies Covered

2 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	0.0%	0 ratings
Hold	66.7%	2 ratings
Sell	33.3%	1 ratings

Out of 3 total stock ratings issued by Matthew Weston at UBS Group, the majority (66.7%) have been Hold recommendations, followed by 33.3% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NYSE	100.0% of companies on NYSE	2 companies

Matthew Weston, an analyst at UBS Group, currently covers 2 companies listed on , with the majority traded on NYSE.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 2 companies	100.0%

Matthew Weston of UBS Group specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
LARGE CAP PHARMA 2 companies	100.0%

Matthew Weston's Ratings History at UBS Group

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
NVO Novo Nordisk A/S	8/5/2025	Downgrade	$48.86		Neutral	$0.00 00.00% ROI
NVS Novartis	2/13/2025	Reiterated Rating	$106.98		Neutral	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.